COMMITMENTS AND CONTINGENCIES (Tables)

9 Months Ended

Sep. 30, 2024

Commitments and Contingencies Disclosure [Abstract]

Schedule of Contingent Consideration

A reconciliation of the opening balances to the closing balances of these Level 3 measurements for the nine months ended September 30, 2024 and September 30, 2023 is as follows (in thousands):

Nine Months Ended September 30, 2024	Contingent Consideration Liability Related to Acquisition of:
	Arkis		Location in Financial Statements	Derma Sciences		ACell		Surgical Innovations Associates (SIA), Inc.		Location in Financial Statements
Balance as of January 1, 2024	$	15,755		$	2,557	$	300	68,700
Payment								(12,400)
Change in fair value of contingent consideration liabilities	(3,019)		Research and development	137		—		3,100		Selling, general and administrative
Balance as of September 30, 2024	12,736			2,694		300		59,400
Short-Term	$	8,320		$	—	$	—	$	19,600	Accrued expenses and other current liabilities
Long-Term	4,416			2,694		300		39,800		Other liabilities
Total	12,736			2,694		300		59,400

Nine Months Ended September 30, 2023	Contingent Consideration Liability Related to Acquisition of:
	Arkis		Location in Financial Statements	Derma Sciences		ACell		Surgical Innovations Associates (SIA), Inc.		Location in Financial Statements
Balance as of January 1, 2023	$	12,895		$	230	$	3,700	$	57,600
Change in fair value of contingent consideration liabilities	1,991		Research and development	1,887		(2,200)		6,600		Selling, general and administrative
Balance as of September 30, 2023	$	14,886		$	2,117	$	1,500	$	64,200
Short-Term	$	4,373		$	—	$	503	$	13,000	Accrued expenses and other current liabilities
Long-Term	10,513			2,117		997		51,200		Other liabilities
Total	14,886			2,117		1,500		64,200